This article describes a proof of concept study designed to evaluate the potential of an in vivo three-dimensional printing route to support minimally invasive repair of the musculoskeletal system. The study uses a photocurable material to additively manufacture in situ a model implant and demonstrates that this can be achieved effectively within a clinically relevant timescale. The approach has the potential to be applied with a wide range of light-curable materials and with development could be applied to create functionally gradient structures in vivo.
Introduction
The use of minimally invasive techniques for surgical interventions offers clear advantages to both the healthcare system and to the patient. 1 Procedures are generally quicker and the degree of surgical insult is lower, which means that hospital stays and rehabilitation periods are shorter, which in turn offers a faster return to work and society for the patient. For the musculoskeletal system, arthroscopic techniques are commonly used to enable examination, biopsy, debridement and microfracture. In order to seek to repair the musculoskeletal system with minimal invasion, materials which can be injected into the body have been developed, notably cements for vertebroplasty and kyphoplasty procedures, 2 and polymeric or particulate bone defect filling materials. More recently, there has been interest in the arthroscopic delivery of osteochondral plugs to treat small joint defects, 3, 4 but this approach has not yet progressed to clinical adoption.
An alternative approach to bulk injection of a material is to use additive manufacturing to build up a three-dimensional (3D) structure through the sequential formation and bonding of layers of material together. Previous work has shown that additive manufacture can, in principle, be used to fill joint defects 5 but has not yet been explored how this could be achieved minimally invasively. This approach offers potential advantages over existing injectable approaches as it could extend the range of materials which could be processed using a minimally invasive approach, by allowing the use of materials which cure or set more effectively in small volumes. In addition, the approach could be used to develop multi-material structures in order to provide a functionally gradient implant.
A potential methodology for clinical application is outlined schematically in Figure 1 . Preparation of the implant site would involve removing damaged tissue and providing a lining to the defect to temporarily isolate the site while development of the implant took place. Sequential deposition and in situ curing, in this case through blue light, of material would then be used to develop the implant through additive manufacture in vivo. Visible light is non-thermogenic, less damaging to the cells and provides curing at higher depths in comparison to ultraviolet (UV) light. 6, 7 Blue light curing is an attractive approach as it has been clinically applied widely in dentistry and with a higher depth penetration in comparison to violet light. [7] [8] [9] The work presented in this article describes a proof of concept study undertaken to understand whether a blue light-curable material could be effectively delivered arthroscopically in order to fill a model osteochondral defect within a clinically useful timescale. HEMA (hydroxyethylmethacrylate) monomer was chosen as a model material for the study; it is a dental filler material with established blue light cure protocols and well understood cure characteristics. Table 1 details the reagents used to create the HEMA solutions, and Table 2 shows the constitution of the three solutions and the role of the different materials in the blue light cure system. Anseth et al. 10 used a 1-w/v.% in a 1:1 ratio of camphorquinone (CQ) to amine; however, others such as Dewaele et al. 11 have used a 0.5-w/v.% 1:1 ratio. To determine whether the concentration of components in these systems work with the mono methyl ether hydroquinone (MEHQ) inhibited HEMA monomer, the w/v.% and ratio were investigated at these reported values. The solutions were prepared by weighing CQ and ethyl 4-(dimethylamino)benzoate (EDMAB) in an amber glass vial with black polytetrafluoroethylene (PTFE)-faced rubber lined cap (11309493; Thermo Fisher Scientific, Massachusetts USA). Using a pipette, triethylene glycol dimethacrylate (TEGDMA) was then added until it constituted 0.5 mol% of HEMA into the solution. The solution was then mixed for 1 h using an SRT6 Stuart Ò tube roller (Bibby Scientific Ltd, Staffordshire, UK).
Materials and methods

Materials and preparation
Materials processing
Light source. A Cree Ò XLamp Ò XP-E LED (royal blue) 450-465 nm (Cree Inc., Durham, NC, USA) was used with an optical poly(methyl methacrylate) (PMMA) LED lens (FP11085; LEDiL, Salo, Finland). Power was supplied by a British Standards Tester PSM 3/2A three channels regulated DC power supply (BSIgroup, London, UK). The radius of the illumination spot measured was 0.5 cm when it was 1 cm from the lens, and the light-emitting diode (LED) was operated at 734 mA, which gave an estimated power output of 1000 mW/cm 2 .
Mould and photocuring chamber. A two-part PTFE mould was fabricated to provide an array of model defects. The top part of the PTFE mould consisted of an array of nine holes of 8 mm diameter with a 2-mm deep counterbore of 40 mm diameter cut to act as a location feature for the photocuring chamber. The base part of the PTFE mould consisted of an array of pins 8 mm in diameter aligned to fit into the holes in the top part. Upon assembly, the wells were, 8 mm in diameter with 6 mm depth ( Figure 2 ), chosen to be the representative of small osteochondral defects.
The photocuring chamber consisted of a closed 3D-printed polylactic acid (PLA) cylinder of 40 mm diameter with a central 3-mm hole for connecting the LED holder and a 5-mm hole for the wires and nitrogen inlet ( Figure 3 ). The PMMA LED lens was mounted to the XP-LED and attached to an aluminium column with Arctic Silver Ò 5 thermal paste (Visalia, CA, USA).
HEMA polymerisation. The photochemical process of polymerisation depends on the transfer of reactive species generated by the photoinitiator CQ in response to blue light. The transfer of these reactive species from the CQ to the HEMA monomer is facilitated by the tertiary amide EDMAB and leads to propagation of the polymer chain. The presence of oxygen within this system absorbs the reactive species and thus retards initiation and propagation of the reaction. 12 In these experiments, nitrogen gas was used to displace oxygen from the curing chamber to diminish oxygen inhibition of the photocuring process. The intrinsic and extrinsic factors affecting curing efficiency are explained in detail by Leprince et al. 12 In terms of the exposure time, the key factors include the formulation, volume, temperature and irradiance intensity. Ambient temperature was controlled by an air conditioning unit at 20°C.
In previous studies of blue light cure, a range of blue light intensities have been used, ranging from 1 to 3000 mW/cm 2 . 12, 13 The materials used in this study include the MEHQ inhibitor, which is added to dental formulations to provide shelf life. In order to ensure that the processing conditions would mitigate MEHQ inhibition, a relatively high light intensity of 1000 mW/cm 2 was used.
The 10-mm distance of the LED to the maximal curing base was selected as this illuminated the build area effectively. From initial experiments -;1 mm HEMA layers cured into a malleable disc with 1-min exposure time -ergo-controlled prolonged exposure time points were investigated.
To produce ;1-mm-thick layers, 50 mL of the HEMA solution was pipetted into a PTFE mould. The photocuring chamber with flowing nitrogen was then placed over the well as shown in Figure 3 and the power supply was activated to deliver 734 mA equating to 1000 mW/cm 2 at the spot 10 mm from the lens. Therefore, HEMA exposure times were investigated between 1 and 10 min.
For multi-layered experiments, this process was repeated, with no delay between the end of an exposure and the deposition of the material for the next layer, using formulation A, 734 mA, and an exposure time of 1 min.
Material characterisation
Fourier transform infrared spectroscopy. Solid material samples were analysed using an attenuated total reflection-Fourier transform infrared (ATR-FTIR) Perkin Elmer Spectrum 100 with PerkinElmer's Spectrumä v6 FT-IR software. Spectra were collected by cleaning the diamond/ZnSe crystal surface with acetone or 100% ethanol before and after use. The machine was calibrated to background atmosphere prior to data collection. The base of the polymerised HEMA (polyHEMA) samples was then loaded onto the diamond/ZnSe attenuated total reflection (ATR) crystal detection area and locked in place using the pressure arm. All samples were polished using graded abrasive paper to ensure sufficient contact with the ATR crystal. Spectra were then recorded from 4000 to 650 cm 21 with a resolution of 4 cm 21 and a minimum of 32 scans per sample.
The multi-layered samples were bisected using a circular diamond blade. The samples were also polished to ensure contact with the ATR crystal. Measurements were taken centrally at the top and bottom of the samples ( Figure 4) , with the ATR crystal adjacent to the top and bottom surfaces, and centrally in the middle of the samples halfway between the top and bottom measurements.
The degree of conversion (DC) was calculated by comparing the vibrational band of the residual nonpolymerised methacrylate C=C stretching mode at 1638 cm 21 to the aromatic C-C stretching mode at 1710 cm 21 used as an internal standard. The nonpolymerised HEMA solution was used as a reference.
Imaging. The sectioned polyHEMA cylinders were imaged using a Leica M165FC with integrated LED spotlights. Images were acquired and processed using DFC310 FX camera (Leica with the Application Suite (LAS) software; Leica Microsystems GmbH, Heidelberg, Germany).
Superficial heating of the sectioned polyHEMA cylinders was applied using 100°C hot air supplied by a TENMA 21-10125 rework station (Tokyo, Japan). The hot air gun was positioned approximately 1 cm from the sample surface and held for 10-20 s.
Dimensional measurements. The samples were measured using Mitutoyo digimatic calipers 0-150 mm (Mitutoyo, Sakado, Japan).
Compression test. Six-layer polyHEMA cylinders were tested in compression using a H25KS Tinius Olsen Ltd (Surrey, UK) testing machine with a 25-kN load cell. The cylinders were initially trimmed at each end to create parallel surfaces. The crosshead speed was 2 mm/min and samples were tested to failure.
Statistical methods
Collected data were processed and formatted using Microsoft Excel 2016. Statistical data analysis was performed using GraphPad Prism 6 Ò . One-way analysis of variance (ANOVA) was performed using a Tukey's honestly significant difference post hoc test, and two-way ANOVAs were performed when possible to determine variation between data sets.
Results
Curing of single layers
Morphology. Figure 5 shows the polyHEMA discs from formulations A-C with 1-and 4-min exposure times. After 1-min exposure, the polyHEMA discs from formulations A and C have strong yellow colour. All the discs had a meniscus, with some material failing to cover the PTFE mould surface (denoted by the arrows in Figure 5(a) ). Figure 5 (b) shows that apart from those samples where material coverage was incomplete, the diameter of the samples was consistent and not significantly affected by exposure time. 
FTIR and degree of conversion
Multiple layer curing
Morphology. Figure 7(a) shows that the multi-layer polyHEMA cylinders retained the meniscus throughout the addition of further layers. Superficial heating of the cut surface of the polyHEMA plugs revealed curvedlined features correlating with the layer interfaces (Figure 7(b) ). Figure 7 (c) shows that the cylinders were broadly consistent in diameter, although the single-layer specimens were on average around 2% smaller in diameter than the multi-layer specimens. The sequential weight gains were similar to the expected values, as were most of the height gains, apart from layers 4 and 5 where some levelling out of the meniscus seems to occur. Note that the height of layer 1 is misleading: in all cases, the height measurement was at the top of the meniscus. remained consistent throughout, with no significant differences in DC.
Degree of conversion
Mechanical properties
Compression testing with six-layer samples gave an average modulus of 204 MPa (min. 184 MPa, max. 240 MPa) and an average compressive strength of 82 MPa (min. 69 MPa, max. 92 MPa).
Discussion
Effectiveness of the processing route in curing HEMA
The curing of single layers resulted in some incomplete surface coverage, which remained inconsistent. This was most likely caused by poor wettability of the HEMA mixture on the PTFE substrate. However, the single-layer experiments were valuable in showing that the 1-min exposure time was sufficient to stimulate polymerisation of composition A. The sequential layer photopolymerisation processing route produced solid, robust polyHEMA cylinders which filled the model defects, with six-layer cylinders produced in less than 10 min. The average DC of the multi-layer specimens was between 50% and 60%. The DC achieved was typical of blue light cured methacrylate-based dental filler materials (e.g. Galva˜o et al. 14 quote 55% for PMMA processed using conventional dental curing equipment, and Marovic et al. 15 quote around 60% for a range of methacrylate-based materials), so the processing route is considered to have achieved a DC broadly equivalent to that achieved in commercial light-cured materials. We consider that a useful volume of material could be delivered and polymerised in situ at a rate which is clinically practical, so the approach is considered to have clinical promise.
Potential for clinical application
HEMA was used within this study as a model material with which the proof of concept study was performedit does not have the biological properties for clinical application in a musculoskeletal application. In order for the approach to be viable for an orthopaedic application, the process would require the use of materials which would have in vivo properties relevant to the musculoskeletal system. However, there is a significant body of work on photocurable materials which could have clinical application. Table 3 summarises materials which have potential to be applied to the musculoskeletal system using an arthroscopic approach outlined in this article and includes modified HEMA systems which could have potential alongside a range of other materials. For the most part, these materials are not yet commercially available, but there is clear potential for an approach like the one outlined in this article to be adopted for their use. Indeed, several photocurable monomer systems have been used in additive manufacturing of cell -hydrogel constructs outlined in an excellent review by Melchels et al. 16 While the light curing kinetics vary from material system to material system, the rate at which the model plugs could be made within the proof of concept study gives confidence that delivery and cure in situ of a wider range of materials within clinically relevant timescales will be possible. There is also the potential to reinforce the polymers with a nano-scale bioceramic, and with an appropriate material delivery system, functionally gradient composites could be created. The overall material system could be inert and biocompatible, designed to stay as deposited (or bioactive), designed to resorb over time and be replaced with natural tissue, and Table 3 identifies both inert and bioactive materials.
For a range of reasons, we consider that the use of a membrane to isolate the volume within the body where the plug would be delivered would be required. This would avoid the ingress of blood into the build volume, and would mean that monomers would not leach into the surrounding tissue prior to being polymerised. As a result of the feasibility study, a third reason can be identified: the membrane and implant materials should be chosen to avoid the formation of a meniscus. Meniscus formation is controlled by the wettability of the wall material by the contained liquid, so engineering the surface properties of the membrane offers a way of controlling the overall shape of the implant. The choice of membrane material would clearly also depend upon whether an inert or bioactive implant was being developed. For an inert material a PMMA membrane would offer good levels of biocompatibility, whereas for a bioactive implant, there are a range of possible membranes to support tissue regeneration. 38 
Conclusion
In vivo additive manufacture using a minimally invasive approach offers an attractive route to the production of implants for the musculoskeletal system, and we have demonstrated proof of principle for a system based on 19 Hard/soft tissue PHB-co-hydroxyvalerate and HEMA membranes: No in vitro cell/in vivo testing. Polyethers 20 Soft tissue A number of polyethers such as poly(ethylene glycol) (PEG) are used to as part of oligomers and triblock copolymers. PCL-b-PEG-b-PCL:
In vitro assessment for adherence of fibroblasts. Polycaprolactone (PCL) 17, 21, 22 Soft tissue Poly(-caprolactone-co-trimethylene carbonate): In vitro assessment of endothelial cells and cardiomyocytes. Poly(propylene fumarate) (PPF) 23, 24 Hard tissue Bone PFF: 3D-printed structures assessed for 112 days in vitro with fibroblasts. PFF/HEMA/Bioglass: 2D in vitro assessment using human malignant melanoma cells. Bone adhesion mechanical tests. Poly(trimethylene carbonate) (TMC) 21, 22, 25 Soft tissue Cartilage PEG-TMC and TMC-PCL-TMC: Fused filament fabricated 3D scaffolds assessed in vitro with patient-derived human mesenchymal stem cells (MSC). Enzymatic in vitro degradation assay. Poly(TMC-DLLA): In vitro assessment of cardiomyocytes. Polyphosphoesters (PPE) 26 Hard/soft tissue Bone Poly(6-aminohexyl propylene phosphate) (PPE) modified with acylated PEG (PPE-PEG): In vitro: MSC 90% + viability to monomer (max 10 mg/mL). MSC encapsulated in 8-mm-diameter cylinders with 150 mL monomer solution (~3 mm height). Polyanhydrides 10, 27 Hard/soft tissue Bone Poly(sebacic anhydride): In vivo tested (4 days) -material was filled into 2-mm drilled tibia defect in Sprague-Dawley rats. New collagen and blood vessel formation observed around the implant site.
Hydroxyapatite nanoparticle filled polyanhydride -no in vitro cell/in vivo testing. PolyHEMA 28, 29 Soft tissue HEMA and diethylene glycol dimethacrylate: No in vitro study. HEMA grafted with polyamidoamine: In vitro assessment for encapsulating human MSC in a 1-cm diameter and 3mm height. Triblock polymers 20 Hard/soft tissue
In vitro assessments of cell attachment study (2004) . Natural polymers Alginate 30 Soft tissue Alginate methacrylate: No in vitro assessment.
Hyaluronic acid 30, 31 Soft tissue Hyaluronan methacrylate: No in vitro assessment. Gelatin [32] [33] [34] [35] Soft tissue Gelatin methacrylate (GelMA):
In vitro: 5-mm-diameter cylinder with 2 mm thickness. In vivo: C57BL/6J mice; 1 mL injected subcutaneously. Pullulan 36 Soft tissue Pullulan methacrylate. In vitro assessment: Encapsulation of 3T3 fibroblasts, HepG2 liver cells and endothelial cells assessed for viability. Gellan gum 37 Soft/hard tissue Bone Gellan gum methacrylate: In vitro assessment: Adiposederived stem cells encapsulated and assessed using hydrogel on-chip process. Demonstrated in vitro spontaneous differentiation into the osteogenic lineage. Chitosan 7 Soft tissue Methacrylated glycol chitosan:
In vitro assessment: Viability study using chondrocytesinvestigated formulation cytotoxicity and influence of irradiation on encapsulated cells. In vivo assessment: Osteochondral defect explant model -4 mm diameter in New Zealand white rabbit's knees cultured for 14 days.
HEMA: hydroxyethylmethacrylate; PolyHEMA: polymerised HEMA; 2D: two-dimensional; 3D: three-dimensional; PGA: polyglycolic acid; PEO: poly(ethylene oxide); DLLA: d, llactic acid.
light-curable biomaterials. A simple model system has been developed in order to build plugs of appropriate dimensions suitable for the chemical and mechanical characterisation. HEMA, used as a model material, demonstrated that appropriate volumes of material could be delivered within clinically relevant timescales and effectively polymerised in situ, with minimal influence of the sequential layer manufacture process on the DC. A wide range of light-curable biomaterials, with potential for application across the musculoskeletal system using this processing route, are being developed.
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